Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocidib + Oxaliplatin for Relapsed/Refractory Germ Cell Tumors
NCT00957905Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2009
- Primary completion
- Aug 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of alvocidib in germ cell tumor (GCT) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Jun 2009; status: completed.
02
Drugs
alvocidib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00957905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957905.